Intellia TherapeuticsNTLA
Market Cap: $2B
About: Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Employees: 598
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
29% more repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 87
15% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 41
2% more funds holding
Funds holding: 279 [Q1] → 285 (+6) [Q2]
3.7% less ownership
Funds ownership: 97.03% [Q1] → 93.34% (-3.7%) [Q2]
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
21% less capital invested
Capital invested by funds: $2.57B [Q1] → $2.02B (-$552M) [Q2]
32% less call options, than puts
Call options by funds: $18.7M | Put options by funds: $27.6M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
6 analyst ratings
JP Morgan Brian Cheng 60% 1-year accuracy 12 / 20 met price target | 179%upside $55 | Overweight Maintained | 12 Aug 2024 |
RBC Capital Luca Issi 33% 1-year accuracy 16 / 48 met price target | 174%upside $54 | Outperform Maintained | 9 Aug 2024 |
Canaccord Genuity Whitney Ijem 32% 1-year accuracy 9 / 28 met price target | 270%upside $73 | Buy Maintained | 27 Jun 2024 |
Cantor Fitzgerald Rick Bienkowski 22% 1-year accuracy 2 / 9 met price target | 230%upside $65 | Overweight Reiterated | 24 Jun 2024 |
Truist Securities Joon Lee 62% 1-year accuracy 28 / 45 met price target | 509%upside $120 | Buy Maintained | 24 Jun 2024 |
Financial journalist opinion
Based on 3 articles about NTLA published over the past 30 days